Suven Life Sciences has announced grant of 1 product patent from Canada, corresponding to the new chemical entity (NCE), for the treatment of disorders related with Neurodegenerative diseases.

The patent comprises the class of selective 5-HT4 compound and is being developed as therapeutic agents for the treatment of cognitive impairment associated with neurodegenrative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson and Schizophrenia respectively.

Further, Suven CEO, Venkat Jasti stated, “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”

Read EquityPandit’s Techical Analysis of Nifty Pharma Outlook for the Week